Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma

Sponsor
Fudan University
Study ID
NCT07514793
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Mesothelioma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Iparomlimab and Tuvoraleimab injection+Bevacizumab+Pemetrexed+Cisplatin — DRUG
    Iparomlimab and Tuvoraleimab: 5 mg/kg each, on Day 1, intravenous injection, every 3 weeks (Q3W); Bevacizumab: 7.5 mg/kg, on Day 1, intravenous infusion, Q3W; Pemetrexed: 500 mg/m², on Day 1, intravenous infusion, Q3W; Platinum-based agent: either Cisplatin 75 mg/m² on Day 1, intravenous infusion, Q3W, or Carboplatin AUC = 5 on Day 1, intravenous infusion, Q3W; the specific agent is at the investigator's discretion.

Study Details

This is a prospective, single-arm, multicenter, phase II clinical trial designed to evaluate the efficacy and safety of iparomlimab and tuvoraleimab in combination with bevacizumab and chemotherapy as first-line treatment for advanced mesothelioma.

Key Dates

First listed
Apr 7, 2026
Start date
Apr 30, 2026
Status verified
Mar 2026
Primary completion
Apr 30, 2029
Completion
Apr 30, 2029

Study Design

Enrollment
37 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Iparomlimab and Tuvoraleimab injection+Bevacizumab+Pemetrexed+Cisplatin

Primary Outcome Measure

Objective response rate (ORR) [ Time Frame: up to 2 years ]

Central Contacts

Related Studies